查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2017549

獸用抗生素和抗菌劑市場：按類型、動物種類、給藥途徑、劑型和分銷管道分類－2026-2032年全球市場預測

Animal Antibiotics & Antimicrobials Market by Class, Animal Species, Administration Route, Formulation, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，獸用抗生素和抗菌劑市場價值將達到 45.9 億美元，到 2026 年將成長至 48.7 億美元，到 2032 年將達到 74.1 億美元，複合年成長率為 7.08%。

主要市場統計數據
基準年 2025 45.9億美元
預計年份：2026年 48.7億美元
預測年份 2032 74.1億美元
複合年成長率 (%) 7.08%

本文簡要概述了合理使用抗生素、科學進步和監管變革作為塑造獸醫治療的基本力量。

獸醫治療和抗菌藥物管理的發展正在形成科學創新、監管監督和不斷變化的商業性獎勵之間錯綜複雜的相互作用。本執行摘要整合了重塑動物抗生素和抗菌藥物使用的各種因素，重點闡述了管理優先事項、供應鏈韌性和治療方法創新如何融合併重新定義行業實踐。引言部分將這些趨勢置於全球對抗抗菌素抗藥性努力的背景下，同時也強調了持續保護動物健康、福利和生產力的必要性。

診斷技術進步、管理政策和供應鏈數位化如何融合，從而重新定義治療策略和市場參與。

隨著科學、監管、商業性和物流等因素的交織，獸用抗生素和抗菌劑產業正經歷變革，新的操作標準也隨之形成。診斷能力的進步和對標靶治療日益重視，正在減少對頻譜經驗性治療的依賴；同時，對新配方和給藥方法的投資，使得給藥更加精準，殘留更少。同時，政策制定者和獸醫主管部門正在加強監管，並推廣強調謹慎使用、監測和可追溯性的合理用藥框架。這些趨勢促使生產者優先考慮那些既能保證療效又能滿足合理用藥預期的產品系列。

評估 2025 年關稅調整如何重塑動物用藥品。

美國於2025年推出的新關稅和貿易措施進一步加劇了貿易帶來的複雜性，影響了採購、生產決策和雙邊供應關係。關稅調整影響了進口中間體和成品的相對競爭力，促使一些製造商重新評估其籌資策略，檢驗替代供應商，並盡可能加快近岸外包和生產本地化進程。同時，經銷商和飼料廠也被迫調整採購週期和庫存管理，以緩解成本波動，並維持對獸醫和畜牧養殖戶的持續供應。

將治療領域、動物物種特定應用、給藥途徑、製劑和通路與戰略意義聯繫起來的綜合細分見解。

細分市場分析揭示了每種治療類別、動物種類、給藥途徑、製劑和分銷管道的不同促進因素和商業性槓桿，每種情況都需要獨特的策略應對措施。在考慮治療類別時，相關人員必須考慮從Aminoglycosides到四環黴素的廣泛範圍。具體而言，Aminoglycosides包括慶大霉素、新黴素和鏈黴素等亞成分；BETA-內醯胺類包括頭孢菌素類和青黴素類；Fluoroquinolones包括Ciprofloxacin、恩諾沙星和馬波沙星；大環內酯類包括紅黴素、螺旋黴素、胸腺嘧啶和泰樂菌素；磺胺類藥物四環黴素二烷胺類：含四環黴素二甲四環黴素四環黴素。這些分類差異會影響監理風險概況、合理用藥監測、製劑變更的技術障礙。

世界各地在法規、生產系統和供應鏈佈局方面的細微區域差異，正在推動差異化的需求和打入市場策略。

區域趨勢影響產品需求模式、監管執法和供應策略，因此需要採取考慮地理因素的因應措施。在美洲，監管現代化和對資料驅動型管理的重視正在推動對支援合規性和可追溯性的產品和服務的需求。同時，一個強大且一體化的牛肉和家禽產業正在為飼料添加劑和注射劑建立集中通路。歐洲、中東和非洲地區的監管環境複雜多樣，不同司法管轄區的管制政策各異，對進口的依賴造成了脆弱性，同時也為能夠實現殘留監測和低溫運輸完整性的技術提供了機會。在這個一體化區域的許多地區，協調統一的努力與各國的具體規定並存，因此需要靈活的註冊和市場准入方法。

製造商之間的競爭行為和策略需求揭示了為什麼研發平台、服務商品搭售和製造柔軟性是市場上的關鍵差異化因素。

企業層面的趨勢反映了廣泛的策略立場，涵蓋了從垂直整合的成熟企業到專業學名藥生產商和靈活的生物技術新興企業。主要企業正在投資平台能力建設，以縮短重組產品的上市時間並加強對監管要求的合規性，而中小企業和契約製造則專注於在細分治療領域和飼料產品方面實現成本競爭力。診斷服務提供者和治療藥物生產商之間的策略合作正在成為一項關鍵趨勢，透過提供結合治療藥物和決策支援工具的捆綁式解決方案，提升了獸醫和生產者的價值提案。

採取務實的跨部門方法，協調研發、監管合作和商業策略，以加強管理、供應韌性和市場應對力。

行業領導企業必須採取一系列綜合方法，協調產品開發、監管合作和商業性執行，以應對瞬息萬變的抗生素市場。企業應優先投資於診斷關聯治療方法和改進的給藥系統，以提高給藥準確性並降低抗藥性產生的可能性，同時增強自身能力，以支持管理文件和可追溯性。此外，加強供應商多元化並探索區域生產方案，有助於緩解貿易相關的成本壓力，並確保為終端用戶提供持續服務。

透明的調查方法結合了與主要相關人員的對話、監管文件的審查以及系統的分析框架，確保了可操作和檢驗的見解。

本報告的調查方法結合了定性專家訪談、二手文獻整合、監管文件審查以及結構化的相關人員諮詢，以確保獲得可靠且可操作的見解。主要資訊來源包括與執業獸醫、生產經理、製造和分銷專業人員以及監管事務專家的討論，以了解實際情況和新興趨勢。二手分析整合了公開的監管文件、技術專題論文和同行評審文獻，以檢驗不同治療領域和目標物種的臨床、安全性和藥物管理方面的考慮因素。

簡潔地闡述了管理調整、技術採用和在地化供應策略如何共同決定未來的競爭地位。

總之，獸用抗生素和抗菌劑市場正因技術和商業性創新而煥發活力，這些創新為疾病預防和治療開闢了新途徑，但同時也受到日益成長的監管期望的限制。整合診斷工具、靈活製劑能力以及符合監管理念的價值提案的相關人員將更有能力滿足監管要求和客戶期望。同時，區域差異和貿易政策趨勢凸顯了地理平衡的採購和打入市場策略的重要性，這些策略既能確保供應的連續性，又能滿足當地的合規要求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：獸用抗生素和抗菌劑市場：依類別分類

  • Aminoglycosides
    • 慶大霉素
    • 新黴素
    • 鏈黴素
  • BETA-內醯胺
    • 頭孢菌素
    • 青黴素
  • Fluoroquinolones
    • Ciprofloxacin
    • 恩諾沙星
    • 馬波沙星
  • 大環內酯類
    • 紅黴素
    • 螺旋黴素
    • 奇爾米考辛
    • 泰樂菌素
  • 磺胺類藥物
    • 磺胺二甲氧嗪
    • 磺胺二甲嗪
  • 四環黴素
    • 四環黴素
    • 多西環素
    • 四環黴素
    • 四環黴素

第9章：以動物種類分類的獸用抗生素和抗菌劑市場

  • 水產養殖
  • 牛
  • 伴侶動物
  • 家禽
  • 豬

第10章：獸用抗生素和抗菌劑市場（依給藥途徑分類）

  • 飼料添加劑
  • 卵內給藥
  • 注射藥物
  • 口服
  • 外用
  • 水溶性

第11章：獸用抗生素和抗菌劑市場（依劑型分類）

  • Bolus
  • 液體
  • 粉末
  • 預混合料

第12章：獸用抗生素和抗菌劑市場：依分銷管道分類

  • 飼料廠
  • 線上
  • 藥局
  • 動物醫院

第13章：獸用抗生素和抗菌劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：獸用抗生素和抗菌劑市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：獸用抗生素和抗菌劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國獸用抗生素和抗菌劑市場

第17章：中國獸用抗生素和抗菌藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • American Regent Inc.
  • Ayurvet
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale
  • Chanelle Pharma
  • Dechra Pharmaceuticals PLC
  • Eco Animal Health Group PLC
  • Elanco Animal Health Incorporated
  • Eli Lilly and Company
  • Endovac Animal Health, LLC
  • Hester Biosciences Limited
  • Hipra Laboratories, SA
  • Inovet Group
  • Neogen Corporation
  • Norbrook Laboratories Ltd.
  • Novartis AG
  • Phibro Animal Health Corporation
Product Code: MRR-031BF22F949D

The Animal Antibiotics & Antimicrobials Market was valued at USD 4.59 billion in 2025 and is projected to grow to USD 4.87 billion in 2026, with a CAGR of 7.08%, reaching USD 7.41 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.59 billion
Estimated Year [2026] USD 4.87 billion
Forecast Year [2032] USD 7.41 billion
CAGR (%) 7.08%

A concise orientation that frames antimicrobial stewardship, scientific progress, and regulatory evolution as the foundational forces shaping animal therapeutics

The evolution of veterinary therapeutics and antimicrobial management presents a dense landscape of scientific innovation, regulatory scrutiny, and shifting commercial incentives. This executive summary synthesizes the drivers reshaping animal antibiotic and antimicrobial use, focusing on how stewardship priorities, supply chain resilience, and therapeutic innovation are converging to redefine industry practice. The introduction frames these dynamics against the backdrop of global efforts to curb antimicrobial resistance, while also recognizing the enduring need to protect animal health, welfare, and productivity.

Readers will find an integrated perspective that connects class-specific therapeutic discussions with practical considerations across animal species and administration routes. By situating recent regulatory milestones and trade policy developments alongside technological advances in formulation and diagnostic support, this section primes stakeholders to understand both immediate operational impacts and the strategic inflection points that will influence medium-term planning. The intent is to equip leaders with a concise orientation before delving into detailed segmentation, regional nuance, corporate behavior, and evidence-based recommendations.

How converging advancements in diagnostics, stewardship policy, and supply chain digitalization are redefining therapeutic strategy and market engagement

Industry transformation is underway as multiple vectors-scientific, regulatory, commercial, and logistical-intersect to produce new operating norms for animal antibiotics and antimicrobials. Advances in diagnostic capability and a growing emphasis on targeted therapy are reducing reliance on broad-spectrum empiric treatments, while investments in novel formulations and delivery methods are enabling more precise dosing and reduced residues. Concurrently, policy makers and veterinary authorities are tightening oversight and promoting stewardship frameworks that emphasize judicious use, surveillance, and traceability. These developments are prompting manufacturers to prioritize product portfolios that can demonstrate both efficacy and alignment with stewardship expectations.

On the commercial front, supply chain reconfiguration and digitalization are changing how products reach end users. Enhanced traceability systems and e-prescription platforms are facilitating adherence to prescribing rules, while manufacturers and distributors explore value-added services such as diagnostic support, data analytics, and outcome-based contracts. Moreover, the emergence of alternative approaches-such as immunomodulators, probiotics, and precision nutrition-introduces competitive pressure on traditional antibiotic classes. Taken together, these shifts are not incremental; they represent a structural reorientation that requires companies to rethink product development, market access strategies, and customer engagement models.

Assessment of how 2025 tariff adjustments have reshaped sourcing, production allocation, and commercial positioning across the animal therapeutics value chain

The introduction of new tariffs and trade measures in the United States in 2025 has added an overlay of trade-driven complexity that affects procurement, manufacturing decisions, and bilateral supply relationships. Tariff adjustments have influenced the relative competitiveness of imported intermediates and finished formulations, prompting some manufacturers to reassess sourcing strategies, validate alternative suppliers, and accelerate nearshoring or regionalization of production where feasible. In parallel, distributors and feed mills have had to adapt procurement cycles and inventory management to mitigate cost volatility and maintain continuity of supply for veterinarians and livestock operations.

Consequently, pricing dynamics at the wholesale and distributor level have experienced pressure, which in turn has implications for downstream decisions about therapeutic selection and administration routes. For example, products that can be integrated into water-soluble or feed-based delivery systems may gain operational advantages when logistical costs for injectable supplies rise. At the same time, firms with diversified formulation capabilities and flexible manufacturing footprints are better positioned to absorb tariff-induced cost shifts without disrupting service levels. The cumulative impact of the tariffs therefore extends beyond immediate cost increments; it is catalyzing strategic adjustments in sourcing, manufacturing allocation, and commercial positioning across the value chain.

Integrated segmentation insights that map therapeutic classes, species-specific use, administration routes, formulations, and distribution pathways to strategic implications

Segmentation analysis reveals differentiated drivers and commercial levers across therapeutic class, animal species, administration route, formulation, and distribution channel, each demanding distinct strategic responses. When examining therapeutic class, stakeholders must account for the spectrum from aminoglycosides to tetracyclines, with subcomponents such as gentamicin, neomycin, streptomycin among the aminoglycosides and cephalosporins and penicillins within the beta-lactams; fluoroquinolones include ciprofloxacin, enrofloxacin, and marbofloxacin; macrolides encompass erythromycin, spiramycin, tilmicosin, and tylosin; sulfonamides feature sulfadimethoxine and sulfamethazine; and tetracyclines include chlortetracycline, doxycycline, oxytetracycline, and tetracycline. These class distinctions influence regulatory risk profiles, stewardship scrutiny, and technical barriers to reformulation.

Turning to animal species, demand patterns and administration norms differ markedly among aquaculture, cattle, companion animals, poultry, and swine, each exhibiting unique husbandry practices, treatment access points, and sensitivity to residue and withdrawal concerns. Administration routes shape operational use cases: feed additives and water-soluble solutions remain important for herd-level interventions, injectables are preferred for targeted systemic therapy, oral and topical forms serve specific clinical contexts, and in ovo delivery is a niche yet critical approach for early-life interventions in poultry. Formulation types such as bolus, liquid, powder, and premix present different manufacturing, stability, and dosing challenges that affect shelf life and ease of use. Distribution channels create distinct pathways to end users: feed mills serve integrated production systems, pharmacies and veterinary clinics provide professional dispensing, and online channels are expanding access and convenience for companion animal owners and smallholders. Integrating these segmentation layers enables more nuanced portfolio prioritization, regulatory planning, and commercial articulation tailored to the operational realities of each end-user segment.

How regional regulatory nuance, production systems, and supply chain footprints are driving differentiated demand and market access strategies across global regions

Regional dynamics are shaping product demand patterns, regulatory enforcement, and supply strategies in ways that require geographically informed responses. In the Americas, regulatory modernization and emphasis on data-driven stewardship are driving demand for products and services that support compliance and traceability, while strong integrated beef and poultry industries create concentrated channels for feed-based and injectable therapeutics. Europe, Middle East & Africa present a heterogeneous regulatory landscape where stewardship policies vary by jurisdiction, import dependencies create vulnerabilities, and opportunities exist for technologies that enable residue monitoring and cold-chain integrity. In many parts of this combined region, harmonization efforts coexist with country-specific rules, necessitating flexible registration and market access approaches.

Asia-Pacific is characterized by rapid modernization of veterinary practice, persistent high volumes in aquaculture and poultry production, and growing adoption of digital tools and e-commerce for veterinary supplies. The region's manufacturing capacity and supply chain nodes also play a central role in global sourcing, and regulatory authorities are increasingly aligning with international standards while adapting policies to local disease pressures. Taken together, regional contrasts influence priorities for manufacturing localization, channel partnerships, and the design of stewardship-supporting services that are sensitive to local infrastructure and regulatory expectations.

Competitive behaviors and strategic imperatives among manufacturers revealing why R&D platforms, service bundling, and manufacturing flexibility determine market differentiation

Company-level dynamics reflect a spectrum of strategic postures, ranging from vertically integrated incumbents to specialized generics producers and agile biotechnology entrants. Leading manufacturers are investing in platform capabilities that reduce time-to-market for reformulated products and enhance compliance with stewardship requirements, while smaller firms and contract manufacturers focus on niche therapeutic classes or cost-competitive production for feed-grade products. Strategic partnerships between diagnostic providers and therapeutic manufacturers are emerging as a key pattern, enabling bundled solutions that combine treatment with decision-support tools and thereby strengthen value propositions to veterinarians and producers.

In addition, commercial differentiation increasingly leverages service offerings such as veterinary education, on-farm diagnostics, and tailored dosing protocols to deepen customer relationships and create barriers to commoditization. Supply chain resilience and manufacturing flexibility are also rising as core competitive advantages, particularly for companies that can pivot between bolus, liquid, powder, and premix formats in response to customer needs or regulatory shifts. Finally, intellectual property and regulatory exclusivity strategies remain important for firms investing in novel compounds or proprietary delivery systems, though the timeline to commercialization often depends on the ability to demonstrate robust safety and stewardship-aligned efficacy.

Practical, cross-functional actions that align R&D, regulatory engagement, and commercial tactics to strengthen stewardship, supply resilience, and market responsiveness

Industry leaders must adopt an integrated set of actions that align product development, regulatory engagement, and commercial execution to navigate the evolving antimicrobial landscape. Companies should prioritize investments in diagnostic-linked therapies and reformulated delivery systems that improve dosing precision and reduce the likelihood of resistance development, while simultaneously expanding capabilities to support stewardship documentation and traceability. At the same time, strengthening supplier diversification and considering regional manufacturing options can mitigate trade-related cost pressures and maintain service continuity for end users.

On the commercial side, organizations should build closer partnerships with veterinarians and feed managers through education programs, outcome monitoring, and bundled service offerings that justify premium positioning for stewardship-compatible products. Operationally, firms should standardize stability and residue data packages across formulation types to speed regulatory interactions and support cross-border registrations. Finally, corporate leaders must foster cross-functional governance that integrates regulatory foresight, R&D pipelines, and commercial planning so that portfolio decisions reflect both clinical utility and system-level stewardship responsibilities.

A transparent methodology blending primary stakeholder engagement, regulatory dossier review, and structured analytical frameworks to ensure actionable and validated insights

The research methodology underpinning the report combines qualitative expert interviews, secondary literature synthesis, regulatory dossier review, and structured stakeholder consultations to ensure robust and actionable findings. Primary inputs include discussions with practicing veterinarians, production managers, manufacturing and distribution specialists, and regulatory affairs professionals to capture operational realities and emergent trends. Secondary analysis synthesizes publicly available regulatory documents, technical monographs, and peer-reviewed literature to validate clinical, safety, and stewardship considerations across therapeutic classes and species.

Analytical frameworks used in the study include segmentation mapping to align product attributes with end-user needs, supply chain resilience assessment to evaluate sourcing and manufacturing flexibilities, and scenario analysis to understand potential responses to policy and trade shifts. Cross-validation procedures were applied across data sources to reconcile divergent viewpoints and to triangulate findings. Where applicable, regulatory timelines and guidance documents were reviewed to assess compliance burdens and registration pathways, and methodological transparency was maintained throughout to support reproducibility of the core analytical steps.

A succinct synthesis emphasizing how stewardship alignment, technological adoption, and regionalized supply strategies jointly determine future competitive positioning

In conclusion, the animal antibiotics and antimicrobials landscape is simultaneously constrained by rising stewardship expectations and energized by technological and commercial innovations that open alternative pathways to disease prevention and treatment. Stakeholders who integrate diagnostic tools, flexible formulation capabilities, and stewardship-aligned value propositions will be better equipped to meet regulatory demands and customer expectations. Meanwhile, regional differences and trade policy developments underscore the importance of geographically aware sourcing and market entry strategies that protect supply continuity while meeting local compliance requirements.

Ultimately, the sector's near-term trajectory will be shaped by how effectively companies translate scientific advances into products and services that demonstrate both clinical benefit and stewardship compatibility. Organizations that move quickly to build cross-functional alignment, invest in manufacturing resiliency, and forge practical partnerships with the veterinary community will be best positioned to sustain relevance and create differentiated value in an era of heightened scrutiny and rapid change.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Antibiotics & Antimicrobials Market, by Class

  • 8.1. Aminoglycosides
    • 8.1.1. Gentamicin
    • 8.1.2. Neomycin
    • 8.1.3. Streptomycin
  • 8.2. Beta Lactams
    • 8.2.1. Cephalosporins
    • 8.2.2. Penicillins
  • 8.3. Fluoroquinolones
    • 8.3.1. Ciprofloxacin
    • 8.3.2. Enrofloxacin
    • 8.3.3. Marbofloxacin
  • 8.4. Macrolides
    • 8.4.1. Erythromycin
    • 8.4.2. Spiramycin
    • 8.4.3. Tilmicosin
    • 8.4.4. Tylosin
  • 8.5. Sulfonamides
    • 8.5.1. Sulfadimethoxine
    • 8.5.2. Sulfamethazine
  • 8.6. Tetracyclines
    • 8.6.1. Chlortetracycline
    • 8.6.2. Doxycycline
    • 8.6.3. Oxytetracycline
    • 8.6.4. Tetracycline

9. Animal Antibiotics & Antimicrobials Market, by Animal Species

  • 9.1. Aquaculture
  • 9.2. Cattle
  • 9.3. Companion Animals
  • 9.4. Poultry
  • 9.5. Swine

10. Animal Antibiotics & Antimicrobials Market, by Administration Route

  • 10.1. Feed Additives
  • 10.2. In Ovo
  • 10.3. Injectable
  • 10.4. Oral
  • 10.5. Topical
  • 10.6. Water Soluble

11. Animal Antibiotics & Antimicrobials Market, by Formulation

  • 11.1. Bolus
  • 11.2. Liquid
  • 11.3. Powder
  • 11.4. Premix

12. Animal Antibiotics & Antimicrobials Market, by Distribution Channel

  • 12.1. Feed Mills
  • 12.2. Online
  • 12.3. Pharmacies
  • 12.4. Veterinary Clinics

13. Animal Antibiotics & Antimicrobials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Animal Antibiotics & Antimicrobials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Animal Antibiotics & Antimicrobials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Animal Antibiotics & Antimicrobials Market

17. China Animal Antibiotics & Antimicrobials Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. American Regent Inc.
  • 18.6. Ayurvet
  • 18.7. Bayer AG
  • 18.8. Boehringer Ingelheim GmbH
  • 18.9. Ceva Sante Animale
  • 18.10. Chanelle Pharma
  • 18.11. Dechra Pharmaceuticals PLC
  • 18.12. Eco Animal Health Group PLC
  • 18.13. Elanco Animal Health Incorporated
  • 18.14. Eli Lilly and Company
  • 18.15. Endovac Animal Health, LLC
  • 18.16. Hester Biosciences Limited
  • 18.17. Hipra Laboratories, S.A.
  • 18.18. Inovet Group
  • 18.19. Neogen Corporation
  • 18.20. Norbrook Laboratories Ltd.
  • 18.21. Novartis AG
  • 18.22. Phibro Animal Health Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GENTAMICIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY NEOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY STREPTOMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CIPROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ENROFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MARBOFLOXACIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ERYTHROMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SPIRAMYCIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TILMICOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TYLOSIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFADIMETHOXINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFAMETHAZINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CHLORTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DOXYCYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY OXYTETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY IN OVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY WATER SOLUBLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BOLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PREMIX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FEED MILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. MIDDLE EAST ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 255. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 256. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 257. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 258. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 259. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 260. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 261. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 262. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 263. GCC ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY CLASS, 2018-2032 (USD MILLION)
  • TABLE 278. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY AMINOGLYCOSIDES, 2018-2032 (USD MILLION)
  • TABLE 279. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY BETA LACTAMS, 2018-2032 (USD MILLION)
  • TABLE 280. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2032 (USD MILLION)
  • TABLE 281. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY MACROLIDES, 2018-2032 (USD MILLION)
  • TABLE 282. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY SULFONAMIDES, 2018-2032 (USD MILLION)
  • TABLE 283. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY TETRACYCLINES, 2018-2032 (USD MILLION)
  • TABLE 284. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ANIMAL SPECIES, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS ANIMAL ANTIBIOTICS & ANTIMICROBIALS MARKET SIZE, BY FORMULATION, 2018-2032 (US